JP2014533698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533698A5 JP2014533698A5 JP2014542536A JP2014542536A JP2014533698A5 JP 2014533698 A5 JP2014533698 A5 JP 2014533698A5 JP 2014542536 A JP2014542536 A JP 2014542536A JP 2014542536 A JP2014542536 A JP 2014542536A JP 2014533698 A5 JP2014533698 A5 JP 2014533698A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polymer
- poly
- microparticles
- pla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 229920000642 polymer Polymers 0.000 claims description 49
- 239000011859 microparticle Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 33
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- 229920001710 Polyorthoester Polymers 0.000 claims description 28
- 239000002745 poly(ortho ester) Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 24
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- 229920000526 Poly[1,6-bis(p-carboxyphenoxy)hexane] Polymers 0.000 claims description 12
- 102000025171 antigen binding proteins Human genes 0.000 claims description 12
- 108091000831 antigen binding proteins Proteins 0.000 claims description 12
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 108010081667 aflibercept Proteins 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 229920001610 polycaprolactone Polymers 0.000 claims description 10
- 239000002344 surface layer Substances 0.000 claims description 7
- 229920002732 Polyanhydride Polymers 0.000 claims description 6
- -1 Polyethylene Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000000527 sonication Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000004127 vitreous body Anatomy 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161561525P | 2011-11-18 | 2011-11-18 | |
| US61/561,525 | 2011-11-18 | ||
| PCT/US2012/065735 WO2013075068A1 (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149732A Division JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533698A JP2014533698A (ja) | 2014-12-15 |
| JP2014533698A5 true JP2014533698A5 (enExample) | 2016-01-07 |
| JP6267649B2 JP6267649B2 (ja) | 2018-01-24 |
Family
ID=47295198
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542536A Active JP6267649B2 (ja) | 2011-11-18 | 2012-11-18 | ポリマータンパク質微粒子 |
| JP2017149732A Active JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
| JP2019079952A Active JP6727372B2 (ja) | 2011-11-18 | 2019-04-19 | ポリマータンパク質微粒子 |
| JP2020112359A Active JP7217247B2 (ja) | 2011-11-18 | 2020-06-30 | ポリマータンパク質微粒子 |
| JP2023007775A Active JP7542090B2 (ja) | 2011-11-18 | 2023-01-23 | ポリマータンパク質微粒子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149732A Active JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
| JP2019079952A Active JP6727372B2 (ja) | 2011-11-18 | 2019-04-19 | ポリマータンパク質微粒子 |
| JP2020112359A Active JP7217247B2 (ja) | 2011-11-18 | 2020-06-30 | ポリマータンパク質微粒子 |
| JP2023007775A Active JP7542090B2 (ja) | 2011-11-18 | 2023-01-23 | ポリマータンパク質微粒子 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20130129830A1 (enExample) |
| EP (4) | EP2790681B9 (enExample) |
| JP (5) | JP6267649B2 (enExample) |
| KR (4) | KR102218223B1 (enExample) |
| CN (2) | CN103957898B (enExample) |
| AU (1) | AU2012340107B2 (enExample) |
| BR (1) | BR112014011915B1 (enExample) |
| CA (2) | CA3076725A1 (enExample) |
| DK (3) | DK3574897T3 (enExample) |
| ES (4) | ES2985784T3 (enExample) |
| FI (1) | FI2790681T4 (enExample) |
| HU (2) | HUE048597T2 (enExample) |
| IL (4) | IL277958B2 (enExample) |
| MX (2) | MX362286B (enExample) |
| PL (3) | PL3574897T3 (enExample) |
| PT (2) | PT3574897T (enExample) |
| RU (2) | RU2768492C2 (enExample) |
| SG (2) | SG10202103003RA (enExample) |
| WO (1) | WO2013075068A1 (enExample) |
| ZA (4) | ZA201403379B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| AU2012340107B2 (en) | 2011-11-18 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| MY200764A (en) * | 2015-12-16 | 2024-01-14 | Regeneron Pharma | Compositions and methods of manufacturing protein microparticles |
| SMT202200310T1 (it) | 2015-12-23 | 2022-09-14 | Modernatx Inc | Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
| WO2019099921A2 (en) | 2017-11-17 | 2019-05-23 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2021008983A (es) * | 2019-01-30 | 2021-09-08 | Amgen Inc | Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos. |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US11730793B2 (en) * | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| EP4251128A1 (en) * | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| CN115887760A (zh) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | 一种注射用左旋聚乳酸制备工艺 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2026080597A1 (en) * | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4210529A (en) | 1974-12-26 | 1980-07-01 | Midwest Research Institute | Blood compatible polymers and applications thereof |
| US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
| US4764364A (en) | 1986-02-25 | 1988-08-16 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
| US5104221A (en) | 1989-03-03 | 1992-04-14 | Coulter Electronics Of New England, Inc. | Particle size analysis utilizing polarization intensity differential scattering |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| DK0661989T3 (da) | 1992-09-21 | 1998-03-02 | Upjohn Co | Proteinsammensætninger med vedvarende frigivelse |
| GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
| AU3729295A (en) | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0913177A1 (de) | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
| AU2329199A (en) | 1998-01-29 | 1999-08-16 | Poly-Med, Inc. | Absorbable microparticles |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| WO2001030320A1 (en) | 1999-10-22 | 2001-05-03 | Amgen Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| FR2809309B1 (fr) | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
| MXPA03001092A (es) | 2000-08-07 | 2003-09-25 | Nektar Therapeutics Al Corp | Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada. |
| JP2005500304A (ja) | 2001-06-21 | 2005-01-06 | アルタス バイオロジックス インコーポレイテッド | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
| CN1310671C (zh) * | 2001-07-09 | 2007-04-18 | 安斯泰来制药有限公司 | 缓释注射剂用组合物的制造方法 |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| AU2003217531A1 (en) * | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| DK1581251T3 (da) | 2002-12-31 | 2016-06-27 | Althea Tech Inc | Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf |
| US20040208928A1 (en) * | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
| JP5628467B2 (ja) | 2003-06-26 | 2014-11-19 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 生体分解性徐放性ドラッグデリバリーシステム |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| AU2004277750B9 (en) * | 2003-10-01 | 2010-07-15 | Debio Recherche Pharmaceutique S.A. | Device and method for making particles |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| ES2395035T3 (es) | 2004-08-17 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de la IL-1 |
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7572893B2 (en) | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| CA2588449A1 (en) | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US8877229B2 (en) * | 2005-12-02 | 2014-11-04 | Eyetech Inc. | Controlled release microparticles |
| KR100722607B1 (ko) * | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| DE102006030164A1 (de) | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Pulver |
| DE102006030166A1 (de) | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
| EP1958622A1 (en) | 2006-11-07 | 2008-08-20 | Royal College of Surgeons in Ireland | Method of producing microcapsules |
| US20100318193A1 (en) | 2007-03-08 | 2010-12-16 | Desai Tejal A | Topographically engineered structures and methods for using the same in regenerative medicine applications |
| EP3000434A1 (en) | 2007-03-16 | 2016-03-30 | The Regents Of The University Of California | Nanostructure surface coated medical implants and methods of using the same |
| KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| WO2008153997A1 (en) * | 2007-06-07 | 2008-12-18 | Brookwood Pharmaceuticals, Inc. | Reduced-mass, long-acting dosage forms |
| US8729015B2 (en) | 2007-12-21 | 2014-05-20 | Merck Patent Gmbh | Solid lipid microcapsules containing growth hormone inner core microparticles |
| SG2013054218A (en) | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| CA2757037C (en) | 2009-01-29 | 2019-08-06 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| PT3130396T (pt) * | 2009-03-27 | 2021-05-12 | Bend Res Inc | Processo de secagem por pulverização |
| CN101559041B (zh) | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US8417452B2 (en) | 2009-08-19 | 2013-04-09 | General Motors Llc | System for providing information to an operator of a vehicle |
| KR20120095371A (ko) * | 2009-10-01 | 2012-08-28 | 에보닉 데구사 코포레이션 | 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| PT2600812T (pt) | 2010-08-05 | 2021-11-09 | Forsight Vision4 Inc | Aparelho para tratar um olho |
| WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| CA2833144C (en) | 2011-04-14 | 2020-09-29 | The Regents Of The University Of California | Multilayer thin film drug delivery device and methods of making and using the same |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AU2012340107B2 (en) | 2011-11-18 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| SI2849723T1 (sl) | 2012-05-18 | 2018-09-28 | Genentech, Inc. | Formulacije z visoko koncentracijo monoklonskih protiteles |
| IN2014DN10765A (enExample) | 2012-05-30 | 2015-09-04 | Univ California | |
| WO2014039964A2 (en) | 2012-09-10 | 2014-03-13 | The Regents Of The University Of California | Compounds and methods for modulating vascular injury |
| JP6419775B2 (ja) | 2013-03-19 | 2018-11-07 | バイオテック ツールズ エスエー | アレルゲン調製物 |
| CA2954773C (en) | 2014-07-14 | 2023-10-03 | Amgen Inc. | Crystalline antibody formulations |
| MX390837B (es) | 2015-10-16 | 2025-03-21 | Regeneron Pharma | Composiciones de proteinas estables. |
| EP3370524A1 (en) | 2015-11-05 | 2018-09-12 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3374361A1 (en) | 2015-11-13 | 2018-09-19 | Novartis AG | Novel pyrazolo pyrimidine derivatives |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| US20170158901A1 (en) | 2015-12-07 | 2017-06-08 | Celanese International Corporation | Cellulose acetate film forming compositions |
| AU2016371600B2 (en) | 2015-12-15 | 2021-02-18 | Merck Sharp & Dohme Llc | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| MY200764A (en) | 2015-12-16 | 2024-01-14 | Regeneron Pharma | Compositions and methods of manufacturing protein microparticles |
-
2012
- 2012-11-18 AU AU2012340107A patent/AU2012340107B2/en active Active
- 2012-11-18 KR KR1020207003704A patent/KR102218223B1/ko active Active
- 2012-11-18 DK DK19180351.9T patent/DK3574897T3/da active
- 2012-11-18 KR KR1020147014549A patent/KR102133352B1/ko active Active
- 2012-11-18 DK DK18173299.1T patent/DK3384903T3/da active
- 2012-11-18 PL PL19180351T patent/PL3574897T3/pl unknown
- 2012-11-18 ES ES22150172T patent/ES2985784T3/es active Active
- 2012-11-18 HU HUE12795967A patent/HUE048597T2/hu unknown
- 2012-11-18 HU HUE18173299A patent/HUE051644T2/hu unknown
- 2012-11-18 PL PL18173299T patent/PL3384903T3/pl unknown
- 2012-11-18 PL PL12795967.4T patent/PL2790681T5/pl unknown
- 2012-11-18 RU RU2018101248A patent/RU2768492C2/ru active
- 2012-11-18 EP EP12795967.4A patent/EP2790681B9/en active Active
- 2012-11-18 ES ES12795967T patent/ES2775104T5/es active Active
- 2012-11-18 EP EP19180351.9A patent/EP3574897B1/en active Active
- 2012-11-18 MX MX2014005997A patent/MX362286B/es active IP Right Grant
- 2012-11-18 IL IL277958A patent/IL277958B2/en unknown
- 2012-11-18 KR KR1020217004470A patent/KR20210021112A/ko not_active Ceased
- 2012-11-18 KR KR1020227014819A patent/KR20220063293A/ko active Pending
- 2012-11-18 BR BR112014011915-5A patent/BR112014011915B1/pt active IP Right Grant
- 2012-11-18 CN CN201280056324.6A patent/CN103957898B/zh active Active
- 2012-11-18 EP EP18173299.1A patent/EP3384903B1/en active Active
- 2012-11-18 WO PCT/US2012/065735 patent/WO2013075068A1/en not_active Ceased
- 2012-11-18 ES ES18173299T patent/ES2810003T3/es active Active
- 2012-11-18 CA CA3076725A patent/CA3076725A1/en active Pending
- 2012-11-18 CN CN201610035281.3A patent/CN105688188A/zh active Pending
- 2012-11-18 PT PT191803519T patent/PT3574897T/pt unknown
- 2012-11-18 SG SG10202103003RA patent/SG10202103003RA/en unknown
- 2012-11-18 US US13/680,069 patent/US20130129830A1/en not_active Abandoned
- 2012-11-18 CA CA2855749A patent/CA2855749C/en active Active
- 2012-11-18 PT PT181732991T patent/PT3384903T/pt unknown
- 2012-11-18 RU RU2014124682A patent/RU2642664C2/ru active
- 2012-11-18 FI FIEP12795967.4T patent/FI2790681T4/fi active
- 2012-11-18 ES ES19180351T patent/ES2909777T3/es active Active
- 2012-11-18 JP JP2014542536A patent/JP6267649B2/ja active Active
- 2012-11-18 SG SG11201402152YA patent/SG11201402152YA/en unknown
- 2012-11-18 IL IL303832A patent/IL303832A/en unknown
- 2012-11-18 DK DK12795967.4T patent/DK2790681T4/da active
- 2012-11-18 EP EP22150172.9A patent/EP4026543B1/en active Active
-
2014
- 2014-04-29 IL IL232328A patent/IL232328B/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03379A patent/ZA201403379B/en unknown
- 2014-05-16 MX MX2019000382A patent/MX2019000382A/es unknown
-
2017
- 2017-03-06 US US15/450,335 patent/US11291636B2/en active Active
- 2017-08-02 JP JP2017149732A patent/JP6549653B2/ja active Active
-
2018
- 2018-01-05 ZA ZA2018/00078A patent/ZA201800078B/en unknown
- 2018-10-28 IL IL262651A patent/IL262651B/en active IP Right Grant
-
2019
- 2019-04-19 JP JP2019079952A patent/JP6727372B2/ja active Active
-
2020
- 2020-02-05 ZA ZA2020/00742A patent/ZA202000742B/en unknown
- 2020-06-30 JP JP2020112359A patent/JP7217247B2/ja active Active
-
2022
- 2022-02-22 US US17/677,282 patent/US11951216B2/en active Active
-
2023
- 2023-01-23 JP JP2023007775A patent/JP7542090B2/ja active Active
-
2024
- 2024-01-30 ZA ZA2024/00983A patent/ZA202400983B/en unknown
- 2024-03-07 US US18/598,435 patent/US20240207194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7217247B2 (ja) | ポリマータンパク質微粒子 | |
| Su et al. | PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application | |
| Han et al. | Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading | |
| De Geest et al. | Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection | |
| Miladi et al. | Particles from preformed polymers as carriers for drug delivery | |
| Bachelder et al. | Acetalated dextran: a tunable and acid-labile biopolymer with facile synthesis and a range of applications | |
| Zaric et al. | Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses | |
| US11576862B2 (en) | Methods and compositions for preparing a silk microsphere | |
| JP6912377B2 (ja) | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 | |
| Hu et al. | PEGylated-PLGA nanoparticles coated with pH-responsive tannic acid–Fe (III) complexes for reduced premature doxorubicin release and enhanced targeting in breast cancer | |
| Thomas et al. | Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles | |
| US11213490B2 (en) | Encapsulation-free controlled protein release system | |
| KR20160003212A (ko) | 면역 관용의 유도를 위한 특정된 약역학적 유효 수명을 갖는 면역억제제 및 항원의 전달 | |
| JP2014518200A5 (enExample) | ||
| CN109890420A (zh) | 用于递送治疗剂的血小板组合物和方法 | |
| CN111601592A (zh) | 尼古丁纳米疫苗及其用途 | |
| JP2015515968A5 (enExample) | ||
| Parida et al. | Microparticles based drug delivery systems: preparation and application in cancer therapeutics | |
| Albisa et al. | Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery | |
| Kunkel et al. | Injectable controlled‐release systems for the prevention and treatment of infectious diseases | |
| Debnath et al. | Potential application of bionanoparticles to treat severe acute respiratory syndrome coronavirus-2 infection | |
| Su et al. | Complementary Effects of Porosigen and Stabilizer on the Structure of Hollow Porous Poly (lactic-co-glycolic acid) Microparticles | |
| Baxendale et al. | Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology | |
| CA2912730A1 (en) | Methods to produce particles comprising therapeutic proteins | |
| Lacinski et al. | Optimizing the synthesis of interleukin‐12‐loaded PLGA nanospheres (rmIL‐12ns) via ultrasonication for treatment of metastatic osteosarcoma |